Zhengjun Li

Dr. Zhengjun Li


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HSHuiling Su
Huiling Su
JJJing Jia
Jing Jia
YMYuxiang Mao
Yuxiang Mao
RZRiran Zhu
Riran Zhu
ZLZhengjun Li
Zhengjun Li
The clinical application of conventional doxorubicin (CDOX) was constrained by its side effects. Liposomal doxorubicin was developed to mitigate these limitations, showing improved toxicity profiles. However, the adverse events associated with liposomal doxorubicin and CDOX have not yet been comprehensively evaluated in clinical settings. The FAERS data from January 2004 to December 2022 were collected to analyze the adverse events of liposomal doxorubicin and CDOX. Disproportionate analysis and Bayesian analysis were employed to quantify this association. Our analysis incorporated 68,803 adverse event reports related to Doxil/Caelyx, Myocet and CDOX. The relative odds ratios (RORs, 95%CI) for febrile neutropenia associated with CDOX, Doxil/Caelyx, and Myocet were 42.45 (41.44; 43.48), 17.53 (16.02; 19.20), and 34.68 (26.63; 45.15) respectively. For cardiotoxicity, they were 38.87(36.41;41.49), 17.96 (14.10; 22.86), and 37.36 (19.34; 72.17). For Palmar-Plantar Erythrodysesthesia (PPE), the RORs were 6.16 (5.69; 6.68), 36.13 (32.60; 40.06), and 19.69 (11.59; 33.44). Regarding onset time, significant differences adverse events including neutropenia, PPE, pneumonia and malignant neoplasm progression. This study indicates that clinical monitoring for symptoms of cardiotoxicity of CDOX and Myocet, and PPE and interstitial lung disease of Doxil should be performed. Additionally, the onset time of febrile neutropenia, malignant neoplasm progression, and pneumonia associated with Doxil and Myocet merits particular attention. Continuous surveillance, risk evaluations, and additional comparative studies between liposomal doxorubicin and CDOX were recommended.

1 May 2025 in Materials Today Bio
Verified
Journal Article
Open access
HXHongjin Xue
Hongjin Xue
YLYunqian Li
Yunqian Li
XMXinyu Ma
Xinyu Ma
QZQi Zhang
Qi Zhang
JZJunkai Zhu
Junkai Zhu
ZMZhen Mu
Zhen Mu
Psoriasis is a chronic skin condition with significant unmet medical needs, characterized by high levels of reactive oxygen species (ROS) and accompanying oxidative stress. In this study, we developed a novel single-atom iron nanozyme (Fe-N3), designed to mimic natural antioxidant enzymes, for the effective treatment of psoriasis. By optimizing the local coordination environment of Fe atoms, Fe-N3 demonstrated superior superoxide dismutase (SOD), catalase (CAT), ascorbate peroxidase (APx), and glutathione peroxidase (GPx)-like activities compared to Fe-N4. These properties enable efficient ROS scavenging and oxidative stress alleviation. Theoretical analyses revealed that Fe-N3 possesses lower energy barriers for ROS decomposition, explaining its superior catalytic performance. Furthermore, in vitro and in vivo experiments have demonstrated that Fe-N3 nanozyme exhibited remarkable therapeutic effects with extremely low cytotoxicity, effectively inhibiting pathological epidermal proliferation, downregulating key inflammatory factors, and reducing the expression levels of psoriasis-associated pathway proteins. This work highlights the promise of single-atom nanozymes in the curing of inflammatory skin diseases, advancing the transformative role of nanotechnology in biomedicine.

21 March 2023 in Inflammation
Verified
Journal Article
Closed access
PDF file
XLXueqing Li
Xueqing Li
FCFuqiang Chen
Fuqiang Chen
JJJiaoying Ju
Jiaoying Ju
XYXiran Yin
Xiran Yin
ZYZhenxian Yang
Zhenxian Yang
QSQing Sun
Qing Sun

16 August 2023 in Research Square
Verified
Preprint
Open access
PDF file
ZLZhengjun Li
Zhengjun Li
HSHuiling Su
Huiling Su
JJJing Jia
Jing Jia
YMYuxiang Mao
Yuxiang Mao
RZRiran Zhu
Riran Zhu
The clinical application of doxorubicin (DOX) is constrained by its side effects. Liposomal doxorubicin was developed to mitigate these limitations, showing improved toxicity profiles. However, the adverse events associated with liposomal doxorubicin and CDOX have not yet been comprehensively evaluated in clinical settings. The FAERS data from January 2004 to December 2022 were collected to analyze the adverse events of liposomal DOX and CDOX. Disproportionate analysis and Bayesian analysis were employed to quantify this association. Our analysis incorporated 68,803 adverse event reports related to liposomal doxorubicin and CDOX. The relative odds ratios (RORs, 95%CI) for febrile neutropenia associated with CDOX, Doxil®/Caelyx®, and Myocet® were 42.45(41.44;43.48), 17.53(16.02;19.20), and 34.68(26.63;45.15) respectively. For cardiotoxicity, they were 38.87(36.41;41.49), 17.96(14.10;22.86), and 37.36(19.34;72.17). For Palmar-Plantar Erythrodysesthesia (PPE), the RORs were 6.16(5.69;6.68), 36.13(32.60;40.06), and 19.69(11.59;33.44). Regarding onset time, significant differences adverse events including neutropenia, PPE, pneumonia and malignant neoplasm progression. This study indicates that the use of CDOX warrants careful monitoring for cardiotoxicity, PPE, and interstitial lung disease, especially with Doxil®. Additionally, the onset time of febrile neutropenia, malignant neoplasm progression, and pneumonia associated with liposomal doxorubicin merits particular attention. Continuous surveillance, risk evaluations, and additional comparative studies between liposomal doxorubicin and CDOX are recommended.

29 May 2026 in Cell Death & Disease
Verified
Journal Article
Open access
YLYunqian Li
Yunqian Li
HWHe Wen
He Wen
HZHan Zheng
Han Zheng
YZYunyue Zhen
Yunyue Zhen
JJJing Jia
Jing Jia
ZLZhengjun Li
Zhengjun Li
Cutaneous squamous cell carcinoma (cSCC) is a common and aggressive skin cancer, with treatment options for advanced stages often limited by chemoresistance. Here, we observe a positive correlation between PHF20 expression and the malignancy and tumor grade of cSCC. Functional studies suggest that PHF20 promotes oncogenic phenotypes, including proliferation, invasion, and epithelial-mesenchymal transition. Notably, PHF20 depletion appears to sensitize cSCC cells to chemotherapeutic agents. Mechanistically, we show that PHF20 interacts with and promotes the ubiquitin-mediated degradation of GAS7. This downregulation of GAS7 is associated with nuclear F-actin assembly, a process that has been implicated in DNA damage repair (DDR). Consequently, PHF20 loss stabilizes GAS7, enhances nuclear F-actin assembly, and is accompanied by increased DNA damage accumulation. These in vitro findings were corroborated in vivo, where PHF20 knockdown suppressed tumor growth and increased DNA damage. Together, PHF20 may contribute to the regulation of DDR and chemotherapeutic response, highlighting its potential as a therapeutic target in poorly differentiated cSCC.